Nuvalent reports Q2 2022 net loss of $18.5M; pipeline on track with NVL-520 data expected H2 2022

Nuvalent, Inc.

2022-Q2 EPS reported -$0.75

Net loss of $18.5M ($0.38 per share); cash, equivalents and marketable securities $257.0M expected to fund operations into 2024.
R&D expenses $13.6M, G&A $5.2M for Q2 2022.
Preliminary dose-escalation data from Phase 1 ARROS-1 trial (NVL-520 for ROS1+ NSCLC) anticipated in H2 2022.
Dosing initiated in Phase 1 ALKOVE-1 trial (NVL-655 for ALK+ NSCLC); new preclinical data presented at WCLC 2022.
On track to select two additional development candidates in H2 2022 for ALK compound resistance mutations and HER2 Exon 20 insertions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.